SCHEMBL6489938

SCHEMBL6489938

CC(=O)Nc1cccc(C=O)c1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
ALDH1A1 P00352 3/20 0.46
HPGD P15428 2/20 0.46
POLB P06746 2/20 0.44
KDM4E B2RXH2 2/20 0.44
GPR35 Q9HC97 2/20 0.44
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
PKM P14618 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MAOA P21397 1/20 0.41
PARP14 Q460N5 1/20 0.41
MAPK1 P28482 2/20 0.41
GAA P10253 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3792271 0.83 GPR35 (0.61) CYP2C19ALDH1A1HPGDPOLBKDM4E
SCHEMBL30168159 0.82 CYP2C19 (0.62) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL553680 0.82 CYP2C19 (0.62) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL13812018 0.81 CYP2C19 (0.49) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL11108522 0.81 ALDH1A1 (0.52) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL10290977 0.79 CYP2C19 (0.47) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL8277234 0.79 NPC1 (0.56) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL3612815 0.78 MEN1 (0.67) CYP2C19CYP1A2ALDH1A1HPGDPOLB
SCHEMBL30623497 0.78 MEN1 (0.67) CYP2C19CYP1A2ALDH1A1HPGDPOLB
SCHEMBL13174718 0.78 CYP2C19 (0.46) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951857-B2 Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma FREYNE EDDY JEAN EDGARD 2005-10-04 US disclosed
US-6743792-B2 ANTIINFLAMMATORY AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2004-06-01 US disclosed
US-20030220331-A1 Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma FREYNE EDDY JEAN EDGARD (BE) 2003-11-27 US disclosed
US-20020042416-A1 Antiinflammatory agents FREYNE EDDY JEAN EDGARD (BE) 2002-04-11 US disclosed
CN-1261881-A 6-azauracil derivatives as IL-5 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2000-08-02 CN disclosed
EP-1003729-A1 6-AZAURACIL DERIVATIVES AS IL-5 INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2000-05-31 EP disclosed
WO-1999002504-A1 6-AZAURACIL DERIVATIVES AS IL-5 INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 1999-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042416-A1 Antiinflammatory agents CCR1, CCR6, FPR1 CYP2C19 1257/4885CYP1A2 399/4885CYP3A4 695/4885
US-20030220331-A1 Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma IL6, CCR1, CCR6 CYP2C19 944/4885CYP1A2 473/4885CYP3A4 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.